Pittsburgh, PANCT06069570Now EnrollingIRB Ready

Carcinoma, Non-Small-Cell Lung Cancer Clinical Trial in Pittsburgh, PA

Access cutting-edge carcinoma, non-small-cell lung cancer treatment through this phase 1 clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Kiromic BioPharma Inc.

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access carcinoma, non-small-cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related carcinoma, non-small-cell lung cancer treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this carcinoma, non-small-cell lung cancer clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Carcinoma, Non-Small-Cell Lung Cancer Study in Pittsburgh

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Sponsor: Kiromic BioPharma Inc.

Who Can Participate

Inclusion Criteria

Signed and dated informed consent form.
Male or female, \> 18 years old.
Minimum body weight of 50 kilograms (kg).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis
Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and/or have exhibited intolerance to and/or declined clinically applicable salvage therapies, and/or have declined therapy.
Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.
At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease
All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.
Adequate hematopoietic, hepatic and renal function
Agree to adequate contraception for up to 120 days after the last dose of study drug.
Negative serum pregnancy test for women of childbearing potential
All primary and metastatic disease sites are amenable to LDRT
For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases

Exclusion Criteria

Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.
Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.
Active autoimmune disease requiring immunosuppressive therapy.
Infection requiring systemic treatment within 30 days prior to study Day 1.
History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.
Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.
Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.
Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.
Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.
Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.
Allergy or intolerance to any of the study product ingredients or excipients.
Live vaccines administered within 30 days prior to study Day 1.
Individuals lacking capacity to consent for themselves.
Superior vena cava obstruction
Prior radiation therapy to a selected LDRT treatment site \</= 30 days prior to Day 1.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT06069570) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Non-Small-Cell Lung Cancer Treatment Options in Pittsburgh, PA

If you're searching for carcinoma, non-small-cell lung cancer treatment options in Pittsburgh, PA, this clinical trial (NCT06069570) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced carcinoma, non-small-cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all carcinoma, non-small-cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Pittsburgh, PA

See all lung cancer clinical trials recruiting in Pittsburgh — not just this study.

Browse Lung Cancer Trials in Pittsburgh →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA